Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Neoplasms 3Fallopian Tube Neoplasms 3Prostatic Neoplasms 2Ovarian Neoplasms 2Endometrial Neoplasms 2Carcinoma, Ovarian Epithelial 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Solid Tumor 1Primary Myelofibrosis 1Pathologic Complete Response 1Pancreatic Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multiple Myeloma 1Metastatic Castration Resistant Prostate Cancer 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia 1Leiomyosarcoma 1Glioblastoma 1Colorectal Neoplasms 1

Interventions

Doxorubicin 6Specimen Handling 5pembrolizumab 3Radiotherapy 3Radiation 3Nivolumab 3Magnetic Resonance Spectroscopy 3Gemcitabine 3Biopsy 3liposomal doxorubicin 2eribulin 2Ifosfamide 2toripalimab 1talimogene laherparepvec 1rucaparib 1ribociclib 1regorafenib 1peposertib 1pazopanib 1olaratumab 1olaparib 1lenvatinib 1futibatinib 1durvalumab 1dinutuximab 1cemiplimab 1cediranib 1cabozantinib 1avelumab 1anlotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leiomyosarcoma × rucaparib × 1 year × Clear all
NCT04624178 2025-11-20

A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
20 enrolled
Sarcoma

Leiomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡